Understanding how payers value a quality-adjusted life year (QALY) is crucial. We often are asked about the Swedish payer TLV’s willingness to pay (WTP) thresholds for one QALY, and whether the usually cited levels of WTP by severity are used in practice. Have another look at our ISPOR poster where we looked at 101 decisions since 2014 to see which incremental cost-effectiveness ratio (ICER) levels were accepted across different levels of disease severity.
It turns out that the WTP thresholds applied in practice are largely aligned with the unofficial, but often referred to WTP thresholds of 250,000 SEK for low severity, 500,000 SEK for medium severity, and 750,000 SEK for high severity, and 1,000,000 SEK for very high severity.
The devil is in the details however, and understanding these nuances is vital to a successful market launch in Sweden. Make sure to reach out to our skilled Modelling, Access, and Strategy team to know what to expect as you bring a new medicine to market.
